Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Gottlieb, Alice B. [2 ]
Mendelsohn, Alan M. [3 ]
Parno, Jeff [3 ]
Rozzo, Stephen J. [4 ]
Menter, Martin [5 ]
机构：
[1] Mt Sinai Hosp, Dept Dermatol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Sun Pharmaceut, Mumbai, Maharashtra, India
[4] Sun Pharmaceut Ind, Mumbai, Maharashtra, India
[5] Baylor Scott & White, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
15938
引用
收藏
页码：AB51 / AB51
页数：1
相关论文
共 50 条
  • [21] Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
    Reich, Kristian
    Papp, Kim A.
    Blauvelt, Andrew
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Nograles, Kristine
    Mehta, Anish
    Cichanowitz, Nicole
    Li, Qing
    Liu, Kenneth
    La Rosa, Carmen
    Green, Stuart
    Kimball, Alexa B.
    LANCET, 2017, 390 (10091): : 276 - 288
  • [22] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
  • [23] Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
    Crowley, Jeffrey
    Korman, Neil J.
    Spelman, Lynda
    Igarashi, Atsuyuki
    Gupta, Aditya K.
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Eads, Kimberly M.
    Guenthner, Scott T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB162 - AB162
  • [24] Stability of PASI <3 response to tildrakizumab through 5 years: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, Diamant
    Piaserico, Stefano
    Gaarn Du Jardin, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB113 - AB113
  • [25] Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
    Glover, Holly
    Kucera, Kristine
    Mendelsohn, Alan
    Parno, Jeff
    Rozzo, Stephen
    Ferritto, Frank
    Block, Renata
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [26] Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Iversen, Lars
    Peserico, Andrea
    Pau-Charles, Ignasi
    Blauvelt, Andrew
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
  • [27] Limited changes in hematological parameters during tildrakizumab treatment: Post hoc analysis of data from the Tildrakizumab Psoriasis Clinical Program
    Glover, Holly
    Kucera, Kristine
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Ferritto, Frank
    Block, Renata
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB87 - AB87
  • [28] The maintenance of effect with tildrakizumab over 5 years is independent of baseline characteristics: pooled analysis of the phase 3 studies reSURFACE 1 and reSURFACE 2 in patients with moderate to severe psoriasis
    Thaci, Diamant
    Piaserico, Stefano
    Diemert, Sebastian
    Torres, Tiago
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 60 - 60
  • [29] Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
    van de Kerkhof, Peter C.
    Dauden, Esteban
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB120 - AB120
  • [30] Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest
    Egeberg, Alexander
    Jullien, Denis
    Du Jardin, Kristian Gaarn
    Thaci, Diamant
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
12345